Introduction and aims: Cardiometabolic complications often occur after liver transplantation (LT). ADMA and NO have been identified as markers of endothelial dysfunction and the manifestation of cardiovascular diseases in the general population. Their role in cardiovascular risk assessment after liver transplantation has been poorly evaluated, which is the aim of this study. Patients and methods: This study included 177 patients who were liver transplant candidates. The patients had their clinical and laboratory parameters assessed before and after 6 and 12 months after LT. The incidence and prevalence of cardiovascular diseases along with cardiovascular risk according to SCORE were determined and associated with ADMA and NO. Results: In patients with end-stage liver disease, ADMA and NO concentrations correlate with higher cardiac risk category (p=0.046, p=0.044 respectively). Furthermore, an increase in ADMA (p=0.042), NO (p=0.049), fasting plasma glucose (p=0.017), and HDL- cholesterol (p=0.047) concentrations were identified as predictors of cardiovascular risk, whereas hepatocellular carcinoma was determined as a cofounding biological factor (p=0.044). After LT, a physiological connection of the ADMA/NO pathway was established, identified 6 months after LT (p= 0.011), and persisted further 12 months after LT (p=0.007). No connection of ADMA or NO concentrations with higher cardiovascular risk categories after LT was proven, but HDL- cholesterol concentrations (p=0.047), level of glycemia (p=0.006), and liver cirrhosis before LT (p=0.002) were identified as cofounding cardiovascular risk factors. Conclusion: Although this study determined a connection of ADMA and NO with higher cardiovascular risk in patients with end-stage liver disease, their connection with cardiovascular risk after LT was not proven. Classical cardiovascular risk factors increase the total cardiovascular risk after LT. Further research is needed to establish the possible impact of markers of endothelial dysfunction on cardiovascular diseases and risk increase in later periods after LT.